Shire Is Agnostic On Baxalta's Biosimilars Pipeline As Integration Begins
This article was originally published in The Pink Sheet Daily
Executive Summary
In an interview, CEO Ornskov notes that prioritization of combined company's assets is only just beginning with closing of the $32bn merger.
You may also be interested in...
Bioverativ Hits The Street Ready To Expand In Blood Disorders
Bioverativ will spin out from Biogen Feb. 1 as a biotech focused on rare blood disorders, particularly hemophilia. With two marketed drugs, a lifecycle management strategy and leverage to bring in new assets, CEO John Cox says the company is ready to go it alone.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.